Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.54 |
| ▸ | MET | P08581 | 18/20 | 0.49 |
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 2/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 8/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449858 | 0.87 | AXL (0.52) | AXLMETKDRNTRK1TEK | |
| SCHEMBL2447422 | 0.86 | MET (0.55) | AXLMETKDRNTRK1TEK | |
| SCHEMBL27866380 | 0.80 | BRAF (0.51) | KDRTEK | |
| SCHEMBL3491557 | 0.79 | AXL (0.58) | AXLMETKDRNTRK1TEK | |
| SCHEMBL3490673 | 0.75 | MAPT (0.39) | AXLMETMERTKFGFR1 | |
| SCHEMBL22750203 | 0.75 | AXL (0.75) | AXLMETKDRNTRK1TEK | |
| SCHEMBL2409752 | 0.74 | AXL (0.52) | AXLMETKDRNTRK1TEK | |
| SCHEMBL3658869 | 0.73 | KDR (0.44) | KDRFGFR1FLT1 | |
| SCHEMBL3806761 | 0.73 | MAPK14 (0.53) | KDRNTRK1FLT3 | |
| SCHEMBL5065374 | 0.73 | KDR (0.44) | KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365752-B1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8486951-B2 | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-28 | — | — | US | disclosed |
| US-8278331-B2 | N-acyl ureas exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | AXL 439/4885MET 7/4885KDR 88/4885 |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | AXL 441/4885MET 7/4885KDR 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.